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We investigated human cytomegalovirus pathogene-
sis by comparing infection with the low-passage, en-
dotheliotropic strain VR1814 and the attenuated lab-
oratory strain AD169 in human placental villi as
explants in vitro and xenografts transplanted into
kidney capsules of SCID mice (ie, mice with severe
combined immunodeficiency). In this in vivo human
placentation model, human cytotrophoblasts invade
the renal parenchyma, remodel resident arteries, and
induce a robust lymphangiogenic response. VR1814
replicated in villous and cell column cytotrophoblasts
and reduced formation of anchoring villi in vitro. In
xenografts, infected cytotrophoblasts had a severely
diminished capacity to invade and remodel resident
arteries. Infiltrating lymphatic endothelial cells pro-
liferated, aggregated, and failed to form lymphatic
vessels. In contrast, AD169 grew poorly in cytotro-
phoblasts in explants, and anchoring villi formed
normally in vitro. Likewise, viral replication was im-
paired in xenografts, and cytotrophoblasts retained
invasive capacity, but some partially remodeled blood
vessels incorporated lymphatic endothelial cells and
were permeable to blood. The expression of both
vascular endothelial growth factor (VEGF)-C and basic
fibroblast growth factor increased in VR1814-infected
explants, whereas VEGF-A and soluble VEGF recep-
tor-3 increased in those infected with AD169. Our
results suggest that viral replication and paracrine
factors could undermine vascular remodeling and
cytotrophoblast-induced lymphangiogenesis, con-
1540tributing to bleeding, hypoxia, and edema in preg-
nancies complicated by congenital human cytomega-
lovirus infection. (Am J Pathol 2012, 181:1540–1559;
http://dx.doi.org/10.1016/j.ajpath.2012.08.003)
Human cytomegalovirus (HCMV) is the leading cause of
congenital viral infection, with an incidence in the United
States of approximately 1% to 3% of live births.1 Primary
maternal HCMV infection during gestation poses a 40%
to 50% risk of intrauterine transmission, whereas recur-
rent infection in seropositive mothers rarely causes dis-
ease.2,3 Symptomatic infants (25%) have intrauterine
growth restriction (IUGR) and permanent birth defects,
including neurological deficiencies, retinopathy, and sen-
sorineuronal deafness.4–6 Congenital disease is more
severe when primary maternal infection occurs in the first
trimester.7 IUGR and spontaneous abortion in the ab-
sence of fetal HCMV infection can result from placental
pathology.8–10 Placentas infected in early gestation show
long-standing damage and fibrosis at the uterine-placen-
tal interface, which impairs critical functions and results in
a hypoxic intrauterine environment.10–15 Despite the
prevalence and the medical and societal impact of con-
genital HCMV infection, the mechanisms of virus replica-
tion, pathogenesis, and transplacental transmission are
still unresolved because of the complex nature of placen-
tal development and extreme species specificity of
HCMV, which replicates only in human tissues.
Differentiating/invading cytotrophoblasts switch to an
endothelial phenotype in a process that is similar to vas-
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ecules and proteinases that enable their attachment to
and invasion of the uterus. Interstitial invasion requires
down-regulation of integrins characteristic of epithelial
cells and novel expression of the integrins 11, 51,
and v3.17 Endovascular cytotrophoblasts that remodel
uterine blood vessels transform their adhesion receptor
phenotype to resemble that of endothelial cells, express-
ing vascular-endothelial cadherin, platelet-endothelial
adhesion molecule-1, and vascular endothelial adhesion
molecule-1.16,18 Like endothelial cells, cytotrophoblasts
express substances that influence vasculogenesis and
angiogenesis, including the vascular endothelial growth
factor (VEGF) family ligands VEGF-A and VEGF-C and
receptors VEGFR-1 [fms-like tyrosine kinase 1 (Flt-1)] and
VEGFR-3.19–21 Expression of these molecules changes
as the cells differentiate/invade, and they regulate cy-
totrophoblast survival in the remodeled uterine vascula-
ture. Finally, as hemiallogeneic embryonic/fetal cells, in-
vasive cytotrophoblasts must avoid maternal immune
responses. Their expression of the nonclassical major
histocompatibility complex (MHC) class I molecules HLA-
G22,23 and HLA-C, which have limited polymor-
phisms,24,25 contributes to their lack of immunogenicity.
Previous studies led to a rudimentary understanding of
HCMV infection of the human placenta and identified
several molecular mechanisms that impair functions of
differentiating/invading cytotrophoblasts. HCMV infection
dysregulates the expression of key integrins required for
cell invasiveness,26,27 reduces the expression of matrix
metalloproteinase-9,27 and down-regulates cell-cell and
cell-matrix adhesion molecules,28 including those re-
quired for pseudovasculogenesis16 and vascular remod-
eling.18 The immunosuppressive viral cytokine cmv IL-10
further reduces cytotrophoblast invasion through para-
crine effects that increase IL-10 expression.27,28 Peroxi-
some proliferator-activated receptor  activation by infec-
tion also compromises cytotrophoblast functions.29,30 In
chorionic villi, the neonatal Fc receptor for IgG, ex-
pressed in syncytiotrophoblasts that contact maternal
blood, transcytoses circulating maternal antibodies.31–33
In conjunction with neutralizing titers, developmental ex-
pression of HCMV receptors, EGFR, and integrins34–37
determines susceptibility to infection.33,38–40 HCMV in-
fects spatially distinct populations of cytotrophoblasts
that express 11 and v3 integrins used as surface
receptors.41
How HCMV disseminates to the placenta and the early
stages of pathogenesis in pregnancy are still unresolved
because of the virus’ extreme host range restriction. A
successful approach to overcome the obstacle to studies
of HCMV in vivo has been to infect SCID mice (ie, mice
with severe combined immunodeficiency) that have re-
ceived xenografts of human tissues. Infection of human
fetal thymus/liver under the mouse kidney capsule
showed that medullary epithelial cells are prominent tar-
gets of HCMV replication.42 Thus, dramatic interstrain
differences were evident in replication of low-passage
clinical isolates and laboratory strains in thymus/liver xe-
nografts in vivo.42,43 The strain Toledo replicates to high
titers in implants, whereas the laboratory strains AD169and Towne, serially passaged in fibroblasts, are attenu-
ated and fail to propagate in tissues in vivo.43 AD169
lacks a 15-kb segment of viral genome that encodes at
least 19 open reading frames present in the genomes of
all pathogenic clinical strains.44 A deletion mutant of To-
ledo lacking these sequences, although exhibiting only a
minor growth defect in fibroblasts, fails to replicate in
thymus/liver implants in SCID mice, evidence that genes
in this region are central to infection in vivo.45 HCMV
replication in endothelial and epithelial cells correlates
with determinants specified by ORFs UL128-131A,46,47
which are highly conserved in clinical isolates48 and
which elicit neutralizing antibodies in humans.49,50
Herein, we investigated HCMV pathogenesis in in-
fected human placental villous explants and in xenografts
maintained in vivo. We used a model of human placenta-
tion to investigate the vascular effects of fetal cytotropho-
blasts in human placental villi transplanted beneath the
kidney capsules of SCID mice.21 VR1814, a clinical iso-
late, infected cell column cytotrophoblasts in placental
explants and impaired the formation of anchoring villi in
vitro. In xenografts, VR1814-infected placental cells had
a severely diminished capacity to invade and form lym-
phatic vessels. In striking contrast, AD169 replicated
poorly in villous explants. In SCID mice, AD169-infected
cytotrophoblasts remodeled the resident arteries, but
these were faulty. Our results show, for the first time to our
knowledge, that HCMV genes dispensable for growth in
culture function as determinants of pathogenesis that
could contribute to vascular anomalies that originate in
early placentation.
Materials and Methods
Human Placental Villous Explants, Culture, and
HCMV Infection in Vitro
Approval for this project was obtained from the Institu-
tional Review Board at the University of California, San
Francisco. Protocols involving human fetal and placental
tissue from deliveries at Moffitt Hospital (San Francisco,
CA) and use of animals were approved by the Commit-
tees on Human and Animal Research, respectively. Nor-
mal human placentas (n 3) were obtained from elective
termination of pregnancy (Advanced Bioscience Re-
sources, Alameda, CA). Procedures for preparation of
organ cultures (explants) of human placental villi were
reported.26 Briefly, chorionic villi dissected from placen-
tas at 6 to 8 weeks’ gestational age were cultured on
Millicell-CM inserts (0.4-m pore size; Millipore, Billerica,
MA) coated with Matrigel (BD Biosciences, Bedford, MA)
in explant medium: Dulbecco’s modified Eagle’s medi-
um/F12 (1:1) (Gibco, Carlsbad, CA) with 10% Hyclone
fetal bovine serum (FBS; Thermo Scientific, South Logan,
UT), 1% penicillin-streptomycin, and 1% amino acid. Af-
ter 18 to 20 hours, explants were infected [2  106
plaque-forming units (PFU) per explant] with HCMV
VR1814, a clinical isolate maintained at low passage and
propagated in human umbilical vein endothelial cells,51or AD169, a laboratory strain serially passaged in human
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after infection and fixed in 4% paraformaldehyde (Wako
Chemical USA, Richmond, VA) for histological analysis.
Primary Cytotrophoblast Isolation, Culture, and
HCMV Infection in Vitro
Cells were isolated from second-trimester human placen-
tas by previously described methods.26,52 Briefly, pla-
centas were subjected to a series of enzymatic diges-
tions, which detached cytotrophoblast progenitors from
the stromal cores of the chorionic villi. Cells were then
purified over a Percoll gradient, cultured on substrates
coated with Matrigel, and plated in serum-free medium:
Dulbecco’s modified Eagle’s medium/F12 (1:1), with 2%
Nutridoma (Roche Diagnostics, Indianapolis, IN), 1% so-
dium pyruvate, 1% HEPES, 1% penicillin-streptomycin,
and 0.1% gentamicin (UCSF Cell Culture Facility, San
Francisco, CA).26,52 After 16 hours, cytotrophoblasts
were infected with AD169 or VR1814 at a multiplicity of
infection of 2 and maintained for 3 days.27
In Vivo Transplantation of Human Placental Villi
and HCMV Infection in SCID Mice
Homozygous C.B-17 scid/scid mice (Taconic, German-
town, NY) were the recipients of human chorionic villi
(placentas at 8 to 10 weeks’ gestation). In toto, chorionic
villi dissected from five first-trimester placentas were
transplanted to 65 SCID mice. To determine the optimal
time point for HCMV infection, based on recovery of in-
fectious progeny, placental villi were infected immedi-
ately before transplantation (n  30 mice) or after 3
weeks in vivo (n  22 mice). Mock-infected controls (n 
6 mice) were maintained in vivo for the intervals deter-
mined by the experimental conditions, and titration indi-
cated the controls were virus free. Dissected placental
villi were washed with serum-free medium, infected with
VR1814 (1  106 PFU) for 1 hour, transplanted under the
kidney capsular membrane using surgical methods, and
maintained for 3 weeks after infection in vivo.21,53 Alter-
natively, placental villi were first transplanted and main-
tained in vivo for 4 weeks. At that time, implants were
surgically exposed, injected with virus (100 L, 1  106
PFU), and maintained in vivo an additional 3 weeks. To
study the capacity of virulent and attenuated HCMV
strains to grow in vivo, placental villi were cultured for 18
to 20 hours on Matrigel, infected with VR1814 or AD169
(2  106 PFU), transplanted into SCID mice (n  32
mice), and maintained for 3 weeks. Virus titers used to
infect villous explants and xenografts were determined
empirically (data not shown). Mock-infected control pla-
cental villi were virus free. Mice were housed under
pathogen-free conditions and sacrificed, and kidneys
with implants were recovered. One half of the kidney
implant was immediately fixed in 4% paraformaldehyde
at 4°C for histological analysis, and the other half was
snap frozen and stored at 80°C for titration of progeny.HCMV Titration in Placental Villous Implants in
Vivo Maintained in SCID Mice
Frozen implants were sonicated in 0.5 mL cold Dulbec-
co’s modified Eagle’s medium containing 1% FBS on ice.
Virus titers were determined by serial dilution of tissue
homogenates, followed by rapid infectivity assays on hu-
man foreskin fibroblast monolayers in duplicate.26 Virus
titers were expressed as log10 PFU/g protein of tissue
homogenates.
Immunohistochemistry
Placental villous explants cultured on Matrigel in vitro
and implants from SCID mice were fixed in 4% para-
formaldehyde for 30 minutes and 3 to 6 hours, respec-
tively, followed by sucrose gradients and embedded in
gelatin or optimal cutting temperature compound, re-
spectively. Decidual and placental biopsy specimens
were also fixed and embedded in optimal cutting tem-
perature compound. The tissues were frozen in dry ice
and cut into sections (5 m thick). For double immu-
nostaining, tissue sections were simultaneously incu-
bated with primary antibodies from various species
and detected with fluorescein isothiocyanate– or te-
tramethyl rhodamine isothiocyanate–conjugated sec-
ondary antibodies (Jackson ImmunoResearch, West
Grove, PA). Nuclei were counterstained with DAPI
(Vector Laboratories, Burlingame, CA). Mouse mono-
clonal antibodies to HCMV immediate-early (IE 1&2)
nuclear proteins (CH160) and glycoprotein B (gB) were
produced in the Pereira Lab.54,55 Rat monoclonal anti-
human cytokeratin (clone 7D3) was a generous gift
from Dr. Susan Fisher (University of California, San
Francisco, San Francisco, CA). Mouse monoclonal an-
ti-human HLA-G (clone 4H84) was a gift from Dr. Mi-
chael McMaster (University of California, San Fran-
cisco).23 Rabbit polyclonal anti-integrin 91 was a
generous gift from Dr. Dean Sheppard (University of
California, San Francisco).56 Guinea pig anti-HCMV gB
was a gift from Chiron Corporation (Emeryville, CA).
The following antibodies were obtained from the com-
panies listed: rabbit monoclonal anti-human/mouse
Ki-67 (clone EPR3611; Abcam, Cambridge, MA),
mouse monoclonal anti-human cytokeratin 7 (clone
OV-TL 12/30; Dako, Carpentaria, CA), rabbit polyclonal
anti-mouse lymphatic vessel endothelial hyaluronan re-
ceptor (LYVE-1; Fitzgerald Industries International,
North Acton, MA), rabbit polyclonal anti-human
VEGF-A (A-20) and rabbit polyclonal anti-ephrin B2
(P-20) (Santa Cruz Biotechnology, Santa Cruz, CA),
goat polyclonal anti-human VEGF-C and goat poly-
clonal anti-carcinoembryonic antigen-related cell ad-
hesion molecule 1 (CEACAM1)/CD66a (R&D Systems,
Minneapolis, MN), rat monoclonal anti-mouse CD31
(clone MEC13.3; BD Pharmingen, San Diego, CA), and
Syrian hamster monoclonal anti-mouse podoplanin
(Abcam). Apoptosis was detected by TUNEL using the
In Situ Cell Death Detection Kit, Fluorescein (Roche
Applied Science, Indianapolis, IN).
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Sizes of anchoring villi formed in uninfected controls and
HCMV-infected explants at 3 days after infection were
quantified by measuring the areas of explant outgrowths
from anchoring villi visible in digital photographs. Ex-
plants were photographed by phase-contrast micros-
copy on a Nikon Eclipse TE2000-S microscope (Nikon
Instruments, Melville, NY) equipped with a Kodak DC215
digital camera (Eastman Kodak, Rochester, NY) using a
4 objective (40 total magnification). All digital images
were of the same magnification, dimensions, and pixel
densities. Areas were measured by importing images into
Adobe Photoshop CS5.1 (Adobe Systems Inc., San Jose,
CA), outlining the visible areas of outgrowth from the villi
with the lasso tool, and recording the number of pixels
within the outlined areas from the histogram function (at
cache level 1). Numbers of villi examined are as follows:
mock-infected, n  25; AD169, n  21; and VR1814,
n  43.
Quantification of Cytotrophoblast Interstitial
Invasion into Renal Parenchyma
A total of 15 to 30 sections were prepared from each
placental villous implant in kidneys of SCID mice. Two
centrally located sections were stained with H&E. For
each implant, one entire H&E-stained section was digi-
tally photographed by light microscopy using a 4 ob-
jective lens (40 total magnification) on a Nikon Eclipse
50i microscope equipped with a SPOT 7.4 Slider camera
(Diagnostic Instruments, Sterling Heights, MI). A total of
10 to 20 adjacent images of an entire section were im-
ported into Adobe Photoshop CS5.1 and merged using
the automated photomerge function to generate an im-
age of an entire implant in the kidney parenchyma. The
degree of implant invasion (ie, cytotrophoblast-occupied
kidney parenchyma) was measured by outlining implants
with the lasso tool and recording the number of pixels
outlined (at cache level 1). The total implant area, includ-
ing the portion external to the kidney surface proper, was
measured directly by outlining. The area of cytotropho-
blast-occupied kidney parenchyma was determined by
subtracting the external portion from the total area of the
implant. Placental villous implants were defined in H&E-
stained sections by their morphological characteristics,
which are distinct from those of the kidney parenchyma.
Adjacent sections were immunostained for cytokeratin to
confirm the degree of invasion, including small clusters
and individual cytotrophoblasts that projected deeper
into the parenchyma than the main invasion front.
Quantification of Blood Vessel Sizes
To determine the relative sizes of remodeled blood ves-
sels within implants, H&E-stained sections were photo-
graphed at 40 magnification, and images were ana-
lyzed using Photoshop CS5.1. For each section, the
cross-sectional areas of the five largest discernible ves-sels (ie, those that had clearly defined walls and, in most
cases, erythrocytes) were measured by outlining with the
lasso tool, determining the number of pixels encircled,
and converting pixel area to standard area units (mm2).
Most VR1814-infected implants had few or no discernible
blood vessels. Both average vessel size and total cross-
sectional area of perfusion for these and other implants
lacking discernible vessels were considered 0. To quan-
tify vessel diameter, 26 vessels were measured in six
AD169-infected implants. For many AD169-infected and
control implants, there were no clear distinctions between
large vessels; rather, they appeared to contain networks
of interconnected vessels. The results are expressed as
the average total cross-sectional area of the five largest
discernible vessels in each section, rather than average
individual vessel size, because total area more accu-
rately represents the differences between conditions. In
most cases, the five largest vessels accounted for all
clearly discernible large vessels and, thus, represented a
good approximation of the total vessel area within the
implant.
Quantification of Lymphatic Endothelial Cell
Proliferation in the Renal Parenchyma
Proliferation of mouse lymphatic endothelial cells was
quantified by immunostaining with anti-Ki-67 and anti-
mouse LYVE-1 antibodies. The staining images (200
total magnification) were acquired using a Nikon Eclipse
50i microscope and further analyzed quantitatively using
ImageJ software version 1.44o (NIH, Bethesda, MD) or
Adobe Photoshop CS 5.1. The numbers of LYVE-1– and
Ki-67–positive lymphatic endothelial cells per field were
counted, and the proliferation index was expressed as a
percentage of Ki-67–positive cells.
Quantification of Factors in Conditioned Media
Conditioned media from control and infected cytotropho-
blasts and placental villous explants on Matrigel in vitro
were collected at 1 and 3 days after infection, cleared by
centrifugation, and stored at 80°C. Levels of lymphan-
giogenic factors and chemokines were quantified using a
human VEGF-C enzyme-linked immunosorbent assay
(ELISA) kit (Syd Labs, Malden, MA), basic fibroblast
growth factor (bFGF), human IL-6 Quantikine ELISA kits,
and the human VEGFR3 DuoSet ELISA Development
System (R&D Systems). Bioactive VEGF-A was measu-
red using human VEGF-A BioLISA (eBioscience, San
Diego, CA).
Lymphatic Endothelial Cell Proliferation Assays
Lymphatic endothelial cell proliferation was measured by
MTT cell proliferation assays.57 Human lymphatic endo-
thelial cells (HLECs) isolated from lymph nodes (Scien-
Cell Research Laboratories, Carlsbad, CA) were plated
on fibronectin-coated (1 mg/mL), 96-well plates (5  103
cells per well) in endothelial cell medium (ECM) supple-
mented with endothelial cell growth supplement and 5%
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growth factor medium (GFM), for 3 days, and then
starved for 24 hours in ECM containing 0.5% FBS (control
media). Media were then replaced with 100 L of control
media, with or without recombinant human VEGF-A,
VEGF-C, or bFGF proteins (R&D Systems). ECM supple-
mented with endothelial cell growth supplement and 5%
FBS (GFM) was used as a positive control. After 72 hours’
incubation, 20 L of MTT (5 mg/mL) solution was added
to each well, and the plates were further incubated for 24
hours at 37°C. The media were then removed, 100 L of
dimethyl sulfoxide was added to each well to dissolve the
blue crystals, and absorbance was measured at 562 nm
with a reference filter of 650 nm.
To assess the effect of conditioned media from control
and infected cytotrophoblasts on lymphatic endothelial
cell proliferation, conditioned media from control and in-
fected cells on Matrigel were collected at 2 days after
infection. Starved HLECs were then cultured with a mix-
ture of 50 L of conditioned medium and 50 L of control
medium for 72 hours, and MTT assays were performed.
As a control, we used a mixture (referred to as SF-C for
serum free and control) of 50 L of serum-free medium
(as used for culturing cytotrophoblasts, previously de-
scribed) and 50 L of control medium. To assess the
functional contributions of particular growth factors, cells
were incubated with blocking antibodies (anti-bFGF, 5
g/mL; R&D Systems) or recombinant human Fc chime-
ras (VEGFR-1/Flt-1 and VEGFR-3/Flt-4, 5 g/mL; R&D
Systems) for 30 minutes before the addition of condi-
tioned media. Pilot studies were conducted to determine
effective inhibitory concentrations; concentrations 5
g/mL did not lead to significantly greater inhibition for
any of the three inhibitors. Isotype control antibodies
(goat IgG, 5 g/mL; R&D Systems) and a recombinant
human CD6–Fc chimera (5 g/mL; R&D Systems) were
used as controls.
In the figures, the degree of cell proliferation is ex-
pressed as percentage of control values (from cells cul-
tured in control media). Experiments to assess the effect
of growth factors and cytotrophoblast-conditioned media
were performed at least six times. Results of blocking
experiments are expressed as percentage of values ob-
tained using conditioned media without inhibitors. Block-
ing experiments were performed at least three times. The
significance of differences was determined using the Stu-
dent’s t-test.
Statistical Analysis
Average outcomes were compared between groups de-
fined by time period or treatment type using rank-based
Kruskal-Wallis tests. For replicate outcomes (measured
more than once per individual sample), between-group
comparisons were based on linear regression models for
log-transformed outcomes, with robust variances ac-
counting for possible within-individual correlation in out-
comes. To assess the possible effect of nonnormal out-
come distributions on results, we repeated regression
analyses assuming -distributed outcomes. No major dif-ferences were noted, so only the original regression re-
sults are reported.
The relationship between viral titer and percentage of
infected cytotrophoblasts was determined by the Spear-
man rank correlation coefficient. Statistical data analysis
of the lymphatic proliferation index was performed using
the Pearson’s 2 test.
Box-and-whisker plots were generated in Microsoft Ex-
cel (Microsoft Inc., Redmond, WA) using standard Excel
functions. All box-and-whisker plots were made by divid-
ing data sets into four quartiles (ie, each representing
25% of the data points). The box represents the second
and third quartiles, which are divided by the horizontal
bar representing the median. The whiskers span the first
quartile (from the second quartile box down to the mini-
mum) and the fourth quartile (from the third quartile box
up to the maximum). Any data not included between the
whiskers were plotted as an outlier with a small circle. The
Student’s t-test was used to determine the significance of
the difference in expression between control and HCMV
infection. P  0.05 was considered significant.
Institutional Approvals
Approval for this project was obtained from the Institu-
tional Review Board at the University of California, San
Francisco. Protocols involving human fetal and placental
tissue from deliveries at Moffitt Hospital and use of ani-
mals were approved by the Committees on Human and
Animal Research, respectively.
Results
The Pathogenic HCMV Strain VR1814 Infects
Cytotrophoblasts in Placental Explants and
Impairs Development in Vitro
In the first set of experiments, we infected placental vil-
lous explants with AD169 or VR1814 and compared the
development of anchoring villi in vitro. Representative
mock-infected controls and virus-infected explants are
shown (Figure 1, A–F). The controls developed robust
cell columns and anchoring villi with cytotrophoblasts
that aggregated and attached the explants to the extra-
cellular matrix substrate (Matrigel; Figure 1, A and D).
Surprisingly, AD169-infected explants formed normal-
sized anchoring villi indistinguishable from controls (Fig-
ure 1, B and E). In contrast, VR1814-infected explants
formed spindly cell columns composed largely of individ-
ual cytotrophoblasts on top of the substrate (Figure 1, C
and F). Analysis of cytotrophoblasts within the placental
villi revealed that AD169 infected few cells and ex-
pressed IE1&2 proteins (Figure 1G). Occasional infected
cells also expressed gB, suggesting that replication was
restricted (data not shown). In contrast, many VR1814-
infected cytotrophoblasts expressed IE1&2 (Figure 1, H
and I) and gB (Figure 1J). Invasive cytotrophoblasts dif-
ferentiated and expressed MHC class I HLA-G but were
down-regulated in VR1814-infected cells expressing gB
(Figure 1J), as previously reported.26,28
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tinct levels of infection and gB expression in placental
explants during a 3-day interval, too short for titration of
viral replication, we quantified the differences by count-
ing the number of cytotrophoblasts expressing IE1&2
proteins in the cell columns and anchoring villi (Figure
1K). AD169-infected explants contained a median of 2%
infected cytotrophoblasts, with a 5% maximum. In con-
trast, VR1814-infected placental villi contained a median
of 26% infected cells, with a 67% maximum. To quantify
the effects on development of anchoring villi, we mea-sured the sizes of villi formed by measuring the areas
covered by the villous outgrowths at 3 days after infection
(Figure 1L). Control and AD169-infected explants were
comparable, with median sizes (excluding outliers; see
Materials and Methods) of 12 and 11 relative units for
control and AD169, respectively, and a maximum of ap-
proximately 45 relative units. In contrast, VR1814-in-
fected explants formed significantly smaller villi, with a
median size of 3.6 relative units (ie, 10% the size of
those in control and AD169-infected explants) and a
Figure 1. VR1814, a pathogenic HCMV strain,
infects progenitor cytotrophoblasts in placental
chorionic villous explants, reducing anchoring
villous development. A–C: Villous explants with
anchoring villi. Original magnification,2. D–F:
Higher magnification of the areas marked by the
black dashed box in A–C. Original magnifica-
tion, 100. A and D: Mock-infected controls. B
and E: AD169 infection. C and F: VR1814 infec-
tion. Cytotrophoblasts are immunostained for
expression of cytokeratin (CK) and HCMV
IE1&2 in explants infected with AD169 (blue
dashed box from B) (G) and VR1814 (blue
dashed box from C) (H). Original magnifica-
tion: 40 (H); 200 (I, enlargement of the
boxed area in H.). J: The section adjacent to that
in I is stained for HLA-G and gB. Original mag-
nification, 200. Nuclei are counterstained with
DAPI. K: Number of AD169- and VR1814-in-
fected cytotrophoblasts in cell columns: AD169
(explants, 5; cell columns, 19) and VR1814 (ex-
plants, 6; cell columns, 33). *P  0.0001 (Stu-
dent’s t-test). L: Measurements of anchoring villi
of mock-infected control and AD169- and
VR1814-infected explants: mock-infected con-
trol (explants, 7; counted villi, 25), AD169 (ex-
plants, 7; counted villi, 21), and VR1814 (ex-
plants, 16; counted villi, 43). *P  0.001, **P 
0.0001 (Student’s t-test). Scale bars: 1 mm (A–C);
200 m (D–F); 200 m (G and H); 100 m (I
and J).maximum of 18 relative units (P  0.0001 compared with
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fected cell column cytotrophoblasts of placental explants
and impaired functions of the subpopulation of cells that
contribute to forming anchoring villi, reducing their size.
VR1814 Replicates in Cytotrophoblasts of
Human Placental Villi Transplanted to SCID
Mice
To study VR1814 replication in the tissue environment in
vivo, human placental villi transplanted under the kidney
capsules of SCID mice were subjected to infection. Con-
ditions for optimal viral replication were determined, in-
cluding infection before or after transplantation and the
interval for maintenance of infected implants needed to
recover maximal viral titers. Representative sections of
placental villous implants, infected before transplantation
and harvested at 2 weeks (Figure 2, A and C) and 3
weeks (Figure 2, B and D), are shown. Implants infected
at 4 weeks and harvested 2 weeks after infection (total, 6weeks in vivo) (Figure 2, E and F) are also shown. Under
both conditions, cytotrophoblasts expressed cytokeratin
(Figure 2, A, C, and E), and differentiating cells ex-
pressed HLA-G (Figure 2, B, D, and F). Viral replication
was detected at 2 and 3 weeks after infection as dis-
crete foci of infected cytotrophoblasts expressing
IE1&2 proteins (Figure 2, A, C, and E) and gB (Figure
2, B, D, and F) among 10 to 20 placental cells. Typi-
cally, two or three foci of infected placental cells were
observed in each section of VR1814-infected implants.
Interestingly, VR1814-infected cytotrophoblasts that
expressed gB down-regulated HLA-G in vivo (Figure 2,
D and F), in accord with results from villous explants
(Figure 1J).
Replication of VR1814 was quantified by counting the
number of infected cytotrophoblasts and measuring the
titer of virus recovered from homogenates of implants
(Figure 2G). The number of infected cytotrophoblasts that
expressed HCMV IE1&2 proteins in half of the implants
Figure 2. VR1814 replicates in cytotrophoblasts
of human placental villi transplanted under the
kidney capsules of SCID mice. A and B: Placen-
tal villi are infected before transplantation, with
implants harvested at 2 and 3 weeks after infec-
tion. C and D: Insets from A and B. E and F:
Placental villi are infected 4 weeks after trans-
plantation, harvested at 2 weeks after infection.
A, C, and E: Cytotrophoblasts are immuno-
stained for expression of cytokeratin (CK) and
HCMV IE1&2 proteins in infected cells. B, D,
and F: Differentiating cytotrophoblasts are im-
munostained for expression of MHC class I
HLA-G and HCMV gB in infected cells. Asterisk
indicates gB expression in cytotrophoblasts. G:
Correlation between number of infected cytotro-
phoblasts and titer of virus recovered from im-
plants. The relationship between viral titer and
percentage of cytotrophoblasts (CTBs) infected
is determined by Spearman’s rank correlation
coefficient (n  11). H: Titer of VR1814 recov-
ered from homogenates of 39 villous implants in
human fibroblasts at 3 weekly intervals after
infection: 1 week (n  10), 2 weeks (n  16),
and 3 weeks (n  13). Scale bar  50 m.correlated with the titer of virus recovered from the other
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shows the titer of virus recovered from VR1814-infected
placental villous implants at 1, 2, and 3 weeks after in-
fection (n  39 mice). The results showed that VR1814
replicated in cytotrophoblasts in implants infected before or
after transplantation into SCID mice. Titers of virus recov-
ered from placental villi infected before transplantation
ranged from 2.8 to 6.1 log10 PFU/g of protein. Likewise,
titers recovered after direct inoculation of implants after
transplantation ranged from 3.8 to 6.0 log10 PFU/g of pro-
tein. Median viral yields were 4.35 log10 PFU/g of protein at
both 1 and 2 weeks after infection and 5.0 log10 PFU/g of
protein at 3 weeks after infection. No significant difference in
titers of virus recovered at different time points was found
(Kruskal-Wallis equality-of-populations rank test). The find-
ing that progeny virus recovered did not exceed the input
amount indicated that HCMV infection was extremely lim-
ited in the tissue environment of the human placenta.
Dysregulated Lymphangiogenesis in
VR1814-Infected Placental Implants in Vivo
In human placental villi maintained in SCID mouse kidney
capsules, differentiating cytotrophoblasts induces infiltra-
tion of lymphatic endothelial cells, recapitulating a pro-
cess that occurs during human placentation.21 Afterhaving found that VR1814 replicates in human cytotro-
phoblasts maintained in vivo and alters their differentia-
tion, we considered whether cytotrophoblast functions
associated with lymphangiogenesis were also changed.
To address this possibility, we studied the pattern of
lymphatic vessels in the renal parenchyma transplanted
with human placental villi at 3 weeks after infection with
VR1814. Lymphatic endothelial cells were characterized
by examining the expression of LYVE-1, a cell surface
receptor on lymphatic endothelial cells. Mock-infected
controls formed mostly intact lymphatic vessels with dis-
tinct lumens (Figure 3, A and B). In contrast, VR1814-
infected implants had more aberrant forms, including
partial lymphatic vessels, disorganized aggregates, and
linear arrays of lymphatic endothelial cells (Figure 3,
C–E). In the adult mouse kidney, LYVE-1 was expressed
mainly in lymphatic endothelial cells and a subset of
endothelial cells in the glomerular capillaries.58 Thus, we
examined the expression of two additional markers of
lymphatic endothelial cells, podoplanin and integrin
91, to confirm the identity of abnormal lymphatic en-
dothelial cells in VR1814-infected villous explants. Dou-
ble staining of LYVE-1 and podoplanin showed colocal-
ization in vessel-like structures and amorphous cell
clusters, although LYVE-1 staining in vessels was some-
times discontinuous at the vessel periphery, whereas
Figure 3. Aberrant lymphangiogenesis in
VR1814-infected human placental villi in vivo.
LYVE-1–immunostained lymphatic vessels and
endothelial cells are shown. A and B: Normal
vessels in mock-infected controls. C–E: Aberrant
vessels in VR1814-infected placental implants.
F–H: Co-immunostaining for LYVE-1 and podo-
planin in VR1814-infected placental implants. I
and J: Expression of LYVE-1 and integrin 91
in adjacent sections of a VR1814-infected pla-
cental implant. K: Ki-67 immunostains prolifer-
ating LYVE-1–expressing lymphatic endothelial
cells. L: Proliferation index of lymphatic endo-
thelial cells in mock-infected controls and in-
fected villi. The numbers of LYVE-1– and Ki-67–
positive lymphatic endothelial cells per field are
counted. The proliferation index is expressed as
the percentage of LYVE-1–positive cells that are
also Ki-67 positive. Control implants (n  3,
with 15 fields counted) and VR1814-infected im-
plants (n  9, with 27 fields counted) are
shown. *P  0.003 (Student’s t-test). M and N:
Immunostaining for VEGF-A (M) and VEGF-C
(N) in implants. Scale bars: 20 m (A–J); 5 m
(K); 5 m (M and N). CTB, cytotrophoblast.podoplanin staining was not (Figure 3, F–H). Staining for
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colocalization as well (Figure 3, I and J). These results
indicated that both normal and aberrant vessel structures
identified by LYVE-1 staining included lymphatic endo-
thelial cells. A survey of infected placental implants (n 29)
suggested that the number of lymphatic endothelial cells
was higher compared with controls. In sections immuno-
stained for LYVE-1 and Ki-67 expression, a marker for cell
proliferation, we identified a subpopulation of proliferating
lymphatic endothelial cells (Figure 3K). Quantitative analy-
sis indicated that approximately 14% of the cells were pro-
liferating in infected implants, more than twice the number
observed in mock-infected controls (6%), and the differ-
ence was significant (P  0.003) (Figure 3L).
To determine whether VR1814 replication was associ-
ated with factors that induce lymphatic endothelial cell pro-
liferation and migration in vitro,21 implants were immuno-
stained for VEGF-A and VEGF-C. In selected samples, we
found that infected cytotrophoblasts expressing IE1&2 pro-
teins strongly up-regulated expression of VEGF-A (Figure
3M) and VEGF-C (Figure 3N). Cytotrophoblasts in mock-
infected implants failed to react by immunostaining, sug-
gesting that expression was below the detection limit (data
not shown). Together, the results of these experiments
showed that some infected cytotrophoblasts up-regulate
the production of lymphangiogenic factors that contribute to
cell infiltration and proliferation and could alter vessel for-
mation in vivo.
Reduced Interstitial and Endovascular Invasion
by Cytotrophoblasts in VR1814-Infected
Placental Implants
We reported that HCMV infection impairs the invasive-
ness of primary cytotrophoblasts in vitro.26–28 In the pres-
ent study, we showed that infection of placental villi with
VR1814, but not infection with AD169, impaired the de-
velopment of anchoring villi in vitro (Figure 1, C, F, and L).
Based on these results, we theorized that infection could
reduce interstitial invasiveness of cytotrophoblasts in the
kidney parenchyma. To test this hypothesis, placental villi
were infected with VR1814 or AD169 at 18 to 20 hours
after attachment to Matrigel, then transplanted under the
kidney capsules of SCID mice and maintained for 3
weeks. Representative implants immunostained for cyto-
keratin and CEACAM-1 (CD66a), a surface antigen ex-
pressed by invasive cytotrophoblasts,59 showed the ex-
tent of the kidney parenchyma occupied by the placental
cells (Figure 4). Mock-infected controls showed robust
invasion (Figure 4, A–C). The cytotrophoblast-occupied
area increased from the site of implantation shown at the
left, and the invasion front extended well into the cortex,
with select clusters migrating even more deeply (Figure
4, A–C). Interestingly, cytotrophoblast invasion was un-
changed in AD169-infected implants, as expected from
reduced infection in vivo (Figure 4, D–F). The placental
cells invaded the kidney parenchyma, and the total area
of invasion was comparable to controls (Figure 4, D–F). In
contrast, cytotrophoblasts in VR1814-infected implants
showed a strikingly reduced capacity for invasion in therenal parenchyma (Figure 4, G–I). Often, the cytotropho-
blast invasion front stopped abruptly a short distance
from the implantation site (Figure 4, G–I). Detailed anal-
ysis showed that invasive cytotrophoblasts in controls
up-regulated CEACAM1, which was strongly associated
with the plasma membrane, and expressed cytokeratin in
a cytoplasmic pattern (Figure 4, J and L). Many invasive
cytotrophoblasts in AD169-infected implants also co-ex-
pressed cytokeratin and CEACAM1 (Figure 4K).
Total cytotrophoblast invasion into the renal paren-
chyma was quantified by measuring the visible area
occupied by the implant in sections immunostained for
cytokeratin (Figure 4M). The area of invasion in mock-
infected controls had a median of 49 relative units and
a maximum of 63 relative units. AD169-infected im-
plants were comparable to controls (median, 43 rela-
tive units; maximum, 59 relative units). In contrast,
VR1814-infected implants showed significantly re-
duced invasion (median, 13 relative units; maximum,
58 relative units) (P  0.05) relative to control and
AD169-infected implants. Titers of virus recovered
from infected implants indicated that VR1814 repli-
cated eightfold better than did AD169 and that the
laboratory strain failed to yield sufficient virus to detect
in three of eight implants. Together, these findings
supports and extends the in vitro results, showing sig-
nificant differences between pathogenic and attenu-
ated HCMV strains in the ability to affect the formation
of anchoring villi in explants (Figure 1). The results
suggested that VR1814 replication in cytotrophoblasts
in placental tissue significantly reduced the invasive-
ness of cells in vivo when compared with AD169-in-
fected implants and mock-infected controls.
HCMV Infection Impairs Endovascular
Remodeling of Resident Arteries and the
Functions of Blood Vessels
During the examination of VR1814- and AD169-infected
implants, we observed distinct differences in their ap-
pearance under the kidney capsules. Many AD169-in-
fected implants had a network of blood vessels, visible to
the naked eye, not seen in any VR1814-infected implants
or mock-infected controls. Histological analysis revealed
remarkable differences in the vasculature. Control im-
plants had large, cytotrophoblast-remodeled blood ves-
sels in the renal parenchyma (Figure 5, A and B). In
striking contrast, VR1814-infected implants had mostly
small arteries (Figure 5, C and D), in accord with reduced
cytotrophoblast invasiveness (Figure 4, G–I). Like con-
trols, AD169-infected villi had large blood vessels, but
these were usually congested (Figure 5, E and F). In some
areas, blood leaked into the implant (data not shown), sug-
gesting these remodeled blood vessels were more perme-
able than those in controls. Vessel diameters in AD169-
infected implants averaged 0.25 mm, with many vessel
diameters0.5 mm, whereas those in VR1814-infected im-
plants averaged 0.1 mm. In addition, the cross-sectional
areas of blood vessels within implants were quantified by
measuring the areas of discernible blood vessels (the five
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and Methods). AD169-infected and control implants (n  6
and 4, respectively) had average total cross-sectional areas
of 0.20 and 0.26 mm2, respectively, whereas VR1814-in-
fected implants (n  12) had dramatically lower areas, with
an average total area of 0.04 mm2. Notably, 5 of the 12
VR1814-infected implants had no discernible vessels. Com-
parison of H&E-stained and adjacent immunostained sec-
tions showed that cytokeratin-expressing endovascular cy-
totrophoblasts had replaced the arterial endothelial cells
(Figure 5, G and H). Surprisingly, LYVE-1–expressing lym-
phatic endothelial cells intercalated between the stretches
of endovascular cytotrophoblasts in enlarged blood ves-
sels, suggesting a chimeric vasculature (Figure 5, G andH).
To explore the possibility that differences in remod-
eling could result in differences in sizes of blood ves-
sels and heterogeneous cellular composition, sections
of AD169- and VR1814-infected implants were immu-
nostained for expression of CEACAM1, which is ex-
pressed on invasive cytotrophoblasts,59 and mouse
platelet endothelial cell adhesion molecule 1 (CD31),which is expressed on blood vessels. In both implants,
endothelial cells expressing platelet endothelial cell
adhesion molecule 1 were seen at the periphery and
beyond the cytotrophoblast invasion front (Figure 6, A
and B). In AD169-infected implants, all large- and mod-
erate-diameter blood vessels were occupied by cy-
totrophoblasts that expressed CEACAM1 (Figure 6A).
In VR1814-infected implants, CEACAM1-expressing
cytotrophoblasts were found near villous cores (Figure
6B). Some clustered close to or around or even lined
small blood vessels, with little, if any, change in their
diameters. Most CEACAM1-expressing blood vessels
in AD169-infected implants had larger diameters than
those in VR1814-infected implants and suggested re-
modeling.
Endovascular cytotrophoblasts distinguish between
arteries, which they remodel by inducing apoptosis of
the endothelial and smooth muscle cells, and veins,
with which the cells only superficially interact.60,61 Dif-
ferentiating placental cells express ephrins and Eph
Figure 4. VR1814 infection of human
placental cells impairs cytotrophoblast in-
vasion into the renal parenchyma in SCID
mice. Human placental villi are infected
with AD169 and VR1814 and are trans-
planted under the kidney capsules and
maintained for 3 weeks after infection.
A–C, J, and L:Mock-infected control.D–F
and K: AD169-infected implants. G–I:
VR1814-infected implants. Cytotropho-
blasts are immunostained for cytokeratin
(CK), or CEACAM1 and nuclei are stained
with DAPI. Dashed line denotes bound-
ary between implant and kidney
parenchynma (A–I), and arrow (L) indi-
cates direction of cytotrophoblast inva-
sion into kidney parenchyma. Original
pictures are merged using Photoshop
CS5.1 (A–I). Original magnification: 40
(A, D, and G);100 (B, C, E, F, H, and I);
200 (J–L). M: Box-and-whisker plots
showing the relative area of invasion (ie,
cytotrophoblast-occupied kidney paren-
chyma). Control implants (n 4), AD169-
infected implants (n  6), and VR1814-
infected implants (n  14) are shown.
*P  0.05 (Student’s t-test). BV, blood
vessel; VC, villous core. Scale bars: 100
m (A–I); 50 m (J–L).receptors that enable their interactions with endothelial
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genesis.61–63 To test the hypothesis that these mole-
cules could affect migration of cytotrophoblasts in vivo,
infected implants were immunostained with antibodies
to ephrin B2, which selectively marks arteries, cytoker-
atin, and CEACAM1. An analysis of AD169-infected
implants showed a remodeled blood vessel that was
largely occupied by cytotrophoblasts that expressed
cytokeratin (Figure 6C). Several LYVE-1–positive lym-
phatic endothelial cells were also present in the vessel
wall (Figure 6D). Another blood vessel was even more
heterogeneous and contained arterial endothelial cells
that expressed ephrin B2 (Figure 6C) surrounded by
cytotrophoblasts in the renal parenchyma that ex-
pressed cytokeratin and CEACAM1 in blood vessels
(Figure 6D). LYVE-1–expressing lymphatic endothelial
cells were also assembled into portions of small andlarge blood vessels (Figure 6D). Detailed analysis of
parallel sections revealed that the artery side of this
hybrid blood vessel contained endothelial cells that
expressed ephrin B2 (Figure 6, E, F, and H). Other
areas showed TUNEL staining near endothelial cells
(Figure 6, E, G, and H). An immediately adjacent sec-
tion showed that cytotrophoblasts expressing cytoker-
atin surrounded the artery (Figure 6I) and clustered
near ephrin B2–expressing endothelial cells (Figure 6,
I–K) that were positive for TUNEL staining (Figure 6G).
Together, the results suggest that cytotrophoblasts in
AD169-infected implants induced apoptosis of arterial
endothelial cells, the first step in modifying resident
arteries. Although apoptosis was not found in arteries
when infected implants were examined after 3 weeks in
vivo, remodeling occurred earlier, and blood vessels
Figure 5. VR1814 infection of human placental
cells impairs remodeling of the renal paren-
chyma in an in vivo model of cytotrophoblast
invasion in SCID mice. H&E-stained sections of
mock-infected control implants [A and B (mag-
nified from A)], VR1814-infected implants [C and
D (magnified from C)], and AD169-infected im-
plants [E and F (magnified from E)]. Original
magnification: 100 (A, C, and E); 200 (B, D,
and F). G: AD169-infected implants in H&E-
stained section show remodeled blood vessels.
Arrows and arrowheads indicate correspond-
ing positions in the adjacent section. H: Adja-
cent section immunostains for cytokeratin (CK)
in cytotrophoblasts and LYVE-1 in lymphatic en-
dothelial cells. Original magnification, 100 in
both. BV, blood vessel; VC, villous core. Scale
bars: 100 m (A, C, E, G, and H); 50 m (B, D,
and F).containing cytotrophoblasts formed. However, some
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phatic endothelial cells and were congested and per-
meable to blood, suggesting defective functions.
Infected Primary Cytotrophoblasts and Placental
Villous Explants Up-Regulate Expression of
Lymphangiogenic Molecules in Vitro
Differentiating cytotrophoblasts express lymphangio-
genic molecules19,64 that promote cell survival and stim-
ulate migration of human lymphatic endothelial cells in
vitro,21 including VEGF-A, VEGF-C, and bFGF. In addi-
tion, cytotrophoblasts release IL-6, which stimulates an-
giogenesis and lymphangiogenesis,65 and AD169 infec-
tion increases IL-6 release.66 In the SCID model of human
placentation, we found aberrant lymphangiogenesis in
VR1814-infected implants and faulty vascular remodeling
in AD169-infected implants, suggesting that these pro-
cesses could be affected by lymphangiogenic and an-
giogenic factors. To test this hypothesis, we measured
levels of these factors in conditioned media from VR1814-
and AD169-infected primary cytotrophoblasts and pla-
cental villous explants at 1 and 3 days after infection in
vitro.Regarding VEGF-C (Figure 7A), higher levels were
produced by VR1814-infected cytotrophoblasts at 1 and
3 days after infection (median, 30.7 and 36.3 pg/mL,
respectively) than by AD169-infected cytotrophoblasts
(6.9 and 7.3 pg/mL, respectively) or mock-infected con-
trols (0 and 4.5 pg/mL, respectively). In placental villi
(Figure 7B), infected and control explants made compa-
rable levels of VEGF-C (control, 20.9 pg/mL; VR1814,
23.8 pg/mL; and AD169, 26.0 pg/mL) at 1 day after
infection. At 3 days, VR1814-infected explants tended to
make higher levels of VEGF-C (49.7 pg/mL) than did
control (36.3 pg/mL) or AD169-infected explants (9 pg/
mL). Regarding bFGF (Figure 7C), comparable levels
were produced by VR1814-infected (12.7 pg/mL) and
AD169-infected (10.0 pg/mL) cytotrophoblasts at 1 day
after infection relative to controls (0 pg/mL). At 3 days,
although the level for VR1814 remained slightly elevated
(7.0 pg/mL), the level for AD169 decreased (0 pg/mL). In
placental villi (Figure 7D), much higher bFGF levels were
made in VR1814 infection at 1 day after infection (119.2
pg/mL) than in AD169 infection (25.8 pg/mL, P 0.05) or
controls (10.9 pg/mL, P  0.05). At 3 days, elevated
bFGF levels were maintained in VR1814 infection (71.5
Figure 6. Remodeling of resident arteries de-
fective in AD169-infected placental implants.
Human placental villi infected with AD169 or
VR1814 are transplanted under the kidney cap-
sules of SCID mice and maintained for 3 weeks.
Immunostaining for CEACAM1 and CD31 in
AD169-infected (A) and VR1814-infected (B) im-
plants. Original magnification, 100. C and D:
Immunostaining for ephrin B2 (arrowheads,
dashes) and cytokeratin (CK) (line) (C) and
CEACAM1 (line) and LYVE-1 (dots) (D). Origi-
nal magnification, 200. E and F–H (magnified
from E): Sections adjacent to those in C and D
are evaluated for apoptotic nuclei (green) and
immunostained for ephrin B2. I–K: Sections ad-
jacent to that in E are immunostained for ephrin
B2 and CK. Original magnification: 100 (E);
200 (F–K). All sections are counterstained
with DAPI to identify nuclei. BV, blood vessel;
VC, villous core. Scale bars: 100 m (A–D); 100
m (E); 50 m (F–K).pg/mL, P  0.01 compared with control), and levels in
1 d   
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pared with control). Control values were low at both time
points (1 day, 10.9 pg/mL; and 3 days, 6.2 pg/mL). Re-
garding soluble VEGFR-3 (sVEGFR-3; Figure 7E),
AD169-infected cytotrophoblasts made more at 1 day
after infection (14.3 pg/mL) than did VR1814-infected
cells (3.4 pg/mL) or controls (6.3 pg/mL). At 3 days,
approximately the same levels of sVEGFR-3 were found
in all samples (40.2 to 56.2 pg/mL). In placental villi
(Figure 7F), AD169 infection produced high levels of
sVEGFR-3 at 1 day (20.1 pg/mL) and even higher levels
(72.4 pg/mL) at 3 days, whereas VR1814 infection and
controls produced almost no detectable amounts of
sVEGFR-3 at 3 days (control, 0.7 pg/mL; VR1814, 0 pg/
mL). Regarding bioactive VEGF-A (Figure 7G), infected
and control cytotrophoblasts had similarly low levels (14
to 16 pg/mL). In placental villi (Figure 7H), VR1814 and
AD169 again made low levels of bioactive VEGF-A (16.0
and 16.6 pg/mL, respectively) compared with controls
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*(21.7 pg/mL) at 1 day (P  0.05). Levels in AD169 infec-tion were higher (19.8 pg/mL) than those in VR1814 in-
fection (12.1 pg/mL, P  0.01) and controls (12.8 pg/mL,
P  0.05) at 3 days. Last, regarding IL-6 (Figure 7I), the
levels were similar in VR1814-infected and control cy-
totrophoblasts (control, 62.6 pg/mL at 1 day and 65.2
pg/mL at 3 days; and VR1814, 63.3 pg/mL at 1 day and
73.9 pg/mL at 3 days). Slightly more IL-6 was detected in
AD169-infected cytotrophoblasts (73.8 pg/mL at 1 day
and 80.1 pg/mL at 3 days). Infected and control cytotro-
phoblasts (Figure 7J) had comparable levels (63 to
81 pg/mL) at both time points. Likewise, infected and
control placental villi (Figure 7J) had comparable levels
(72 to 85 pg/mL) at both time points. Together, the results
of these experiments indicate that VR1814 infection in-
creases production of VEGF-C and bFGF, whereas
AD169 increases bFGF, sVEGFR-3, and bioactive
VEGF-A. Interestingly, the differences in levels of cyto-
kines produced by the clinical and laboratory strains
were more pronounced in intact placental villi than in
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Figure 7. Quantification of cytokines from
AD169- and VR1814-infected cytotrophoblasts
and placental villous explants in vitro. Primary
cytotrophoblasts (A, C, E, G, and I) and placen-
tal villous explants (B, D, F, H, and J) are in-
fected after 12 hours on Matrigel. Conditioned
medium is removed at 1 and 3 days (d) after
infection, and factors are quantified using ELISA:
VEGF-C, bFGF, sVEGFR-3, bioactive VEGF-A,
and IL-6. Results are from three to six indepen-
dent experiments. Cont., control.2 3
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Proliferation of Lymphatic Endothelial Cells
After having found aberrant lymphatic vessel formation
and increased numbers of lymphatic endothelial cells in
VR1814-infected implants (Figure 3) and differences in
the production of lymphangiogenic factors in control and
VR1814- and AD169-infected cytotrophoblasts in vitro
(Figure 7), we investigated whether conditioned medium
from VR1814-infected cytotrophoblasts could stimulate
lymphatic endothelial cell proliferation in vitro using MTT
assays. First, HLECs were cultured with recombinant
VEGF-A, VEGF-C, or bFGF. Individual growth factors sig-
nificantly increased cell proliferation in a dose-dependent
manner (Figure 8A). A combination of all three growth
factors had additive effects on cell proliferation (concen-
trations in all refer to combined concentrations of all three
growth factors; ie, the 300 ng/mL bar represents 100
ng/mL each of the three growth factors, and the additive
effect of these can be seen by comparing the 300 ng/mL
bar in all with the 100 ng/mL bars in the three individual
cases). We then compared the effects of conditioned
media from control and VR1814- and AD169-infected
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Figure 8. Quantification of lymphatic endothelial cell proliferation in vitro.
A: Lymphatic endothelial cell proliferation assays are performed on cells
cultured in media with individual growth factors (30, 100, and 300 ng/mL), all
growth factors combined (All; 30, 100, and 300 ng/mL combined, or 10, 33.3,
and 100 ng/mL of each), or conditioned media (CM) from control (Cont.) or
infected cytotrophoblasts (VR, VR1814; AD, and AD169) collected at 48
hours. Cell proliferation data are expressed as percentages of control values
(cells cultured in control media). Experiments (mean  SE) are performed at
least six times in duplicate. *P  0.05, **P  0.01, and ***P  0.001 (Student’s
t-test) for comparisons with cells cultured in control media. Data are shown
for growth factor medium (GFM), ECM supplemented with endothelial cell
growth supplement, and 5% FBS (positive control). †P  0.05 for compari-
sons with cells cultured in a mixture of serum-free and control media (SF-C).
B: Blocking effect of VEGFR1-Fc, VEGFR3-Fc, anti-bFGF antibody, and a
combination of all three (All) on cell proliferation. Data are expressed as
percentages of control values (cells cultured in conditioned medium without
inhibitors). Experiments (mean  SE) are performed at least three times in
duplicate. **P  0.01, ***P  0.001 (Student’s test) for comparisons with cells
cultured in conditioned medium alone.cytotrophoblasts on cell proliferation. We found that con-ditioned medium from VR1814-infected cells significantly
promoted cell proliferation relative to SF-C medium. In
contrast, conditioned medium from control or AD169-
infected cells tended to increase cell proliferation, but
this increase was not statistically significant. By using
inhibitors that specifically block signaling by VEGF-A
(VEGFR1-Fc), VEGF-C (VEGFR3-Fc), and bFGF (anti-
bFGF antibody), we determined the relative contributions
of these three to the growth-stimulating activities of the
various conditioned media. Based on these inhibitor
studies, the activity in control conditioned medium was
attributed mostly to VEGF-A (Figure 8B). In contrast, in
conditioned medium from VR1814-infected cells, the
stimulatory activity could be attributed nearly equally to
VEGF-A and VEGF-C and, to a lesser extent, bFGF. How-
ever, the combination of all three inhibitors did not com-
pletely block cell proliferation, suggesting involvement of
additional factors.
Pathological Characteristics Associated with
Reduced Cytotrophoblast Functions in
Congenital HCMV Infection
While studying placentas from pregnancies complicated
by congenital HCMV infection, we found evidence of
hypoxia resulting from avascular villi and fibrosis, with
elevated levels of VEGF-A and a soluble form of its re-
ceptor, soluble Flt-1, in amniotic fluid.14 We considered
that the defects observed in HCMV-infected implants in
the in vivo human placentation model could occur in hu-
man pregnancy. In a case of congenital infection with
HCMV DNA-positive placental bed biopsy specimens
and premature delivery at 31 weeks’ gestation, immu-
nostaining for cytokeratin showed that invasive cytotro-
phoblasts had moderate (Figure 9, A and B) or sub-
stantial (Figure 9, C and D) HLA-G down-regulation. In
addition, the placental cells exhibited other functional
defects. Adjacent to partially remodeled or unmodified
blood vessels in decidua, H&E staining showed areas
of bleeding and leukocytic infiltration, suggesting in-
flammation (Figure 9, E and F). This pathological char-
acteristic suggested that differentiating/invading cytotro-
phoblasts were functionally impaired in remodeling resident
uterine arteries.
Discussion
Herein, we studied HCMV pathogenesis in explants of
human placental villi infected by a low-passage, endo-
theliotropic clinical strain and a laboratory strain in a
human placentation model of cytotrophoblast-induced
arterial remodeling and lymphangiogenesis. By using
these techniques, we showed, for the first time to our
knowledge, that VR1814 replicates in cytotrophoblasts
within the architecture of the human placenta and exhib-
its pathogenic determinants. Table 1 summarizes HCMV
pathogenesis properties identified in vitro and in vivo. In
placental explants, VR1814 replicates in villous and cell
column cytotrophoblasts that differentiate into invasive
cells and populate anchoring villi. In infected placental
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tial and endovascular cytotrophoblast invasion and im-
paired lymphangiogenesis. In striking contrast, AD169
replicates poorly in villous cytotrophoblasts in explants
and has negligible effects on the formation of anchoring
villi. Likewise, AD169 replication was reduced in human
placental xenografts in SCID mice, and cytotrophoblasts
differentiated and invaded the kidney parenchyma. Some
resident arteries were completely remodeled, whereas
others were only partially remodeled. These chimeric
blood vessels contained resident arterial endothelial
cells, cytotrophoblasts, and lymphatic endothelial cells
and were engorged and permeable to blood, suggesting
functional defects. VR1814-infected explants significantly
increased levels of VEGF-C and bFGF in vitro, which
could explain abnormal lymphatic endothelial cell prolif-
eration and dysregulated lymphangiogenesis. In con-
trast, AD169-infected explants substantially increased
the level of bioactive VEGF-A, which could promote pro-
liferation of lymphatic endothelial cells and their incorpo-
ration into defective blood vessels. Our results suggest
that HCMV replication in the placenta enhances the re-
lease of paracrine factors that dysregulate cell prolifera-
tion and migration and contributes to pathogenesis in the
developing placenta.
In congenitally infected placentas, HCMV replicates in
several cell types, including uterine glandular epithelial
and endothelial cells, decidual cells, and differentiating
cytotrophoblasts in the maternal compartment and villous
cytotrophoblasts, stromal fibroblasts, and endothelialcells in the fetal compartment.14,26,38,39,67 Early studies
with AD169 showed that the laboratory strain infects pri-
mary cytotrophoblasts and down-regulates integrin 11
expression, thereby reducing invasiveness in vitro.26 Re-
garding endotheliotropic clinical strains, VR1814-in-
fected cytotrophoblasts up-regulate cmv IL-10, which
decreases matrix metalloproteinase-9 activity, conse-
quently reducing degradation of the extracellular matrix
and impeding cell migration.27 In addition, quantitative
analysis showed that VR1814-infected cytotrophoblasts
reduce expression of the key integrins and cell-cell
adhesion molecules 1, 5, 9, and VE-cadherin, differ-
entiation antigens whose expression is required for pseu-
dovascularization.18,28,60 Infection in the SCID placenta-
tion model shows, for the first time to our knowledge, that
invasion defects in vitro could affect remodeling of stro-
mal tissue and blood vessels in vivo. The diameter of
blood vessels and the total area within VR1814-infected
implants, indicators of the efficiency of perfusion, were
significantly reduced compared with the controls. These
results have important implications for the development
of IUGR in pregnancies complicated by congenital infec-
tion. Together, reduced vascularization, inflammation,
and fibrinoid deposition could decrease perfusion of
the placental surface, leading to transport defects and
hypoxia.14
Surprising differences were found in the capacity of
the attenuated and low-passage pathogenic strains to
infect cytotrophoblasts, replicate, and progress to late
Figure 9. Placental pathological characteristics
associated with congenital HCMV infection. Pri-
mary maternal infection is identified by serocon-
version in a previously HCMV-seronegative
woman and low IgG avidity (25%) in fol-
low-up tests. A–F: Placental bed biopsy speci-
mens from congenital HCMV infection with fetal
IUGR at 31 weeks’ gestational age. Sections are
stained with antibodies to cytokeratin (CK; A
and C) and differentiation molecule MHC class I
HLA-G (B and D) or H&E (E and F). HLA-G
staining of cytotrophoblasts is positive (70%),
weakly positive (20%), and negative (10%) in
biopsy specimens from the periphery (B) and
center (D) of the placenta. In some sites, HLA-G
staining is punctate (D). E and F: Leukocytic
infiltration and bleeding near partially modified
or unmodified uterine blood vessels (BVs).
MYO, myometrium; WBC, white blood cell.
F¡M, fetal¡maternal. Scale bars: 50 m (A–D);
100 m (E and F).infection with gB expression in intact placental villi. All
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gH/gL, which induce fusion of the virion envelope with the
plasma membrane.34,35 Pathogenic strains express ad-
ditional proteins, UL128-131A, that form a pentameric
complex with gH/gL, facilitating virion attachment and
entry into epithelial and endothelial cells.68–70 In the pres-
ent study, we showed that AD169 was highly impaired in
infection and replication in cell column cytotrophoblasts
(Figure 1, B, E, and G). In earlier studies,33,41 we showed
that the strain Toledo infects villous cytotrophoblasts
and differentiating/invading cells that express EGFR
and integrin 11 or v3, but not cell columns.33,41
Like clinical HCMV isolates, the strain Toledo carries
additional DNA sequences that encode at least 19
genes but have rearrangements of the UL131A gene
sequence.44 Cell columns bridge the gap between the
placenta and the uterus and are suspended in the
intervillous space by homotypic interactions. They ex-
press L-selectin and its carbohydrate ligand, part of a
Table 1. HCMV Pathogenic Features in Infected Human Placenta
Strain Placental
Replication Quantified by Cytotrophoblast
Infection and Virus Titers
VR1814 Infected cytotro
(median, 30%
AD169 Cytotrophoblas
express gB (m
1, G and K)
Cytotrophoblast Invasion in Vitro and
Interstitial Invasion of Renal
Parenchyma in Vivo
VR1814 Anchoring villi r
1, C, F, and L
AD169 Anchoring villi n
and L)
Endovascular Cytotrophoblasts Remodel
Resident Arteries in Vivo
VR1814
AD169
Lymphangiogenesis in Vivo
VR1814
AD169
Factors Promoting Cell Proliferation and
Lymphangiogenesis Induced in Vitro
and in Vivo
VR1814 VEGF-C (Figure
Figure 8) and
and 8)
AD169 sVEGFR-3 (Figu
VEGF-A (Figu
bFGF (Figure
NA, not available; ND, no data.specialized adhesion system activated by shear stressthat maintains cell column integrity during the early
stages of placental development.71 This type of adhe-
sion may also facilitate cytotrophoblast movement in
and exit from cell columns, a prerequisite for uterine
invasion. CEACAM1 mediates homophilic and hetero-
philic interactions with other adhesion molecules, and
its expression in invasive cytotrophoblasts (Figure 4, B,
E, H, and J–L, and Figure 6D) suggests that CEACAM1
may also control cytotrophoblast invasion and interac-
tions with the resident vasculature.59 Regarding the
impact of HCMV infection on cell columns, virus repli-
cation could decrease the population of cytotropho-
blasts capable of progressing further down the differ-
entiation pathway, a prerequisite for interstitial and
endovascular invasion. Infection could also perturb the
specialized adhesive properties of cell columns, limit-
ing the number of cytotrophoblasts that exit. Together,
these events could severely reduce development of
anchoring villi in VR1814-infected explants and the
in Vitro and in Vivo
explants Placental xenografts in SCID mice
sts express gB
re 1, H–K)
Number of infected cytotrophoblasts and
virus titers comparable (Figure 2, G
and H)
ted, but few
, 2%) (Figure
Few cytotrophoblasts infected, and virus
titers extremely low (data not shown)
d size (Figure Cytotrophoblast-occupied area
significantly reduced (Figure 4, G–I
and M)
(Figure 1, B, E, Cytotrophoblast-occupied area
comparable to mock-infected controls
(Figure 4, D–F and M)
Resident arteries unmodified (Figure 5, C
and D)
Incompletely remodeled arteries (Figure
6, C and D), congested and
permeable to blood (Figure 5, E
and F)
LYVE-1–positive lymphatic endothelial
cells proliferate, aggregate, and form
aberrant vessels (Figure 3, C–E, K,
and L)
LYVE-1–positive lymphatic endothelial
cells intercalate with cytotrophoblasts
in remodeled blood vessels (Figure 5,
G and H, and Figure 6, C and D)
nd B, and
(Figures 7D
Infected cytotrophoblasts up-regulate the
expression of VEGF-A and VEGF-C
(Figure 3, M and N)
, bioactive
and 8), and
nd 8)
NDl Villi
villous
phobla
) (Figu
ts infec
edian
educe
)
ormal
NA
NA
NA
NA
7, A a
bFGF
re 7F)
res 7H
s 7D acytotrophoblast population capable of invading the in-
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AJP November 2012, Vol. 181, No. 5terstitium and blood vessels in human placental xeno-
grafts.
Uterine spiral artery remodeling involves endothelial
apoptosis induced by invasive cytotrophoblasts through
Fas/FasL interactions.21,72 However, pathogenic HCMV
strains encode two anti-apoptosis proteins expressed
with immediate-early kinetics. In addition to pUL36/vICA,
a viral inhibitor of caspase 8–induced apoptosis,73,74
pUL37, a viral mitochondria-localized inhibitor of apopto-
sis, protects cells from death induced by a variety of
stimuli.75–79 Abundant expression of pUL36/vICA is de-
tected just a few hours after infection and much earlier
than pUL37/viral mitochondria–localized inhibitor of
apoptosis, which accumulates later in fibroblasts.73,74
Coordinate expression of these proteins could maintain
survival of infected cells by suppressing apoptosis. Rel-
evant to the results in AD169-infected implants, a muta-
tion in UL36/vICA could delay resistance to Fas-mediated
apoptosis.73 Although not formally tested, it is likely that
the anti-apoptotic function was encoded later by pUL37/
viral mitochondria-localized inhibitor of apoptosis. After 3
weeks in vivo, the functional consequences include par-
tially remodeled blood vessels, some of which still con-
tained resident arterial endothelial cells expressing eph-
rin B2 (Figure 6, C, E, F, and H–K). The human
placentation model enabled realization of the anti-apop-
totic determinants in HCMV pathogenesis, for the first
time to our knowledge, and provides a framework to test
the in vivo effects of a mutation in pUL37.
Lymphangiogenic factors have autocrine and para-
crine effects that transduce survival and migratory sig-
nals in lymphatic endothelial cells21,80 and maintain cy-
totrophoblast survival.19,20 Quantification of factors made
in VR1814-infected cytotrophoblasts and explants in vitro
showed that VEGF-C and bFGF levels were elevated
compared with mock-infected controls (Figure 7, A–D). In
the model of cytotrophoblast-induced lymphangiogen-
esis in vivo, these factors and others promote migration of
lymphatic endothelial cells.21 In functional experiments,
we showed that VEGF-A, VEGF-C, and bFGF each had
paracrine effects that increased the proliferation of HLEC
and, in combination, had additive effects (Figure 8A).
Depletion experiments confirmed the contributions of
these factors (Figure 8B). However, failure of the com-
bined inhibitors to completely reduce proliferation indi-
cates the involvement of other factors. Angiogenic factors
are essential for the formation of functional vessels and
expression in a complementary and coordinated manner
to balance stimulatory and inhibitory signals. The in-
creased production of factors that promote lymphatic
endothelial cell proliferation in infected cytotrophoblasts
could lead to aggregation that precludes formation of a
functional lymphatic vasculature (Figure 3, C–G) and
could contribute to placental edema in congenital HCMV
infection.13,15,81,82 In AD169 infection, elevated levels of
bioactive VEGF-A, which increases blood vessel perme-
ability, and sVEGFR-3 (Figure 7, E–H, and Figure 8B)
could reduce vessel function and normal lymphangio-
genesis.83 Moreover, VEGFR-3 antibodies or delivery of
sVEGFR-3-Ig fusion protein by an adenovirus vector in-
hibits angiogenesis by suppressing endothelial sproutingand vascular network formation.84 Accordingly, dysregu-
lated factors could result in blood vessels composed of
both lymphatic endothelial cells and invasive cytotropho-
blasts (Figures 5H and 6D). Not previously described,
this chimeric vasculature was hyperpermeable to blood,
conceivably from incorporation of lymphatic endothelial
cells that have junctions specialized for fluid uptake from
surrounding tissue.85 Blood flow could exert pressure on
the vessel wall, resulting in leakiness. In contrast to re-
cent reports of a role for elevated IL-6 in HCMV-infected
lymphatic endothelial cells in lymphangiogenesis,65 en-
dothelial cell survival and angiogenesis,86 and detection
of increased IL-6 in AD169-infected trophoblasts imme-
diately after infection,14 we found no significant increase
in AD169- and VR1814-infected cytotrophoblasts and vil-
lous explants at either 1 or 3 days (Figure 7, I and J).
Vascular anomalies associated with congenital HCMV
infection found in placentas examined at delivery include
avascular villi and fibrosis that reduce blood flow to the
placental-fetal unit and lead to a condition of intrauterine
hypoxia.12,14 To compensate, placentas increase levels
of VEGF-A, which promotes vascular development in the
villous core.12,14 Congenital HCMV infection is associ-
ated with 15% of stillbirths and death in utero after 20
weeks’ gestation, and the placentas have significant
thrombotic vasculopathy,87,88 evidence that links HCMV
infection to vascular damage and fetal morbidity.89 Con-
genital infection with premature delivery and biopsy
specimens with bleeding near partially modified or un-
modified uterine blood vessels (Figure 9, E and F) sug-
gest that defective endovascular cytotrophoblast inva-
sion can lead to bleeding in the uterine wall. Other
complications of congenital infection include placental
edema and fetal hydrops13,15,81,82 associated with im-
paired placental development that contributes to IUGR
and hypoxia.90 By using the in vivo model of human pla-
centation, we identified dramatic defects in cytotropho-
blast differentiation, invasion, and vascular remodeling
that could reduce perfusion of the placental surface in
utero.26–28 Our results also suggest that paracrine factors
could amplify pathology in the decidua by altering lymp-
hangiogenesis, establishing the human placentation
model as an experimental system with which to interro-
gate determinants of viral pathogenesis. We also antici-
pate that placental explants and xenografts in SCID mice
will be invaluable tools for evaluating human monoclonal
antibodies with HCMV neutralizing activity as potential
treatments that could reduce virus replication and asso-
ciated pathology in the developing placenta.
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